• metastatic breast cancer;
  • positron emission tomography/computed tomography;
  • maximum standardized uptake value;
  • prognosis;
  • overall survival


  1. Top of page
  2. Abstract


In this retrospective, single-institution study, the authors examine the maximum standardized uptake value (SUVmax) on positron emission tomography/computed tomography (PET/CT) images as a prognostic variable in patients with newly diagnosed metastatic breast cancer (MBC).


Patients with ≥1 metastatic lesion on PET/CT images that were obtained within 60 days of their MBC diagnosis between January 1, 2001 and December 31, 2008 were included. Patients were excluded if they had received chemotherapy ≤30 days before the PET/CT images were obtained. Electronic medical reports were reviewed to determine the SUVmax and overall survival. Because of intraindividual variation in the SUV by body site, separate analyses were conducted by metastatic site. Relationships between site-specific PET/CT variable tertiles and overall survival were assessed using Cox regression; hazard ratios for the highest tertile versus the lowest tertile were reported.


In total, 253 patients were identified, and their median age was 57 years (range, 27-90 years). Of these, 152 patients (60%) died, and the median follow-up was 40 months. On univariate analysis, SUVmax tertile was strongly associated with overall survival in patients who had bone metastases (N = 141; hazard ratio, 3.13; 95% confidence interval, 1.79-5.48; P < .001). This effect was maintained on multivariate analysis (HR = 3.19; 95% confidence interval, 1.64-6.20, P = .002) after correcting for known prognostic variables. A greater risk of death was associated with SUVmax tertile in patients who had metastases to the liver (N = 46; hazard ratio, 2.07; 95% confidence interval, 0.90-4.76), lymph nodes (N = 149; hazard ratio, 1.1; 95% confidence interval, 0.69-1.88), and lung (N = 62; hazard ratio, 2.2; 95% confidence interval, 0.97-4.95), although these results were not significant (P = .18, P = .31, and P = .095, respectively).


The current results indicate that PET/CT has value as a prognostic tool in patients with newly diagnosed MBC to bone. Cancer 2012. © 2012 American Cancer Society.


  1. Top of page
  2. Abstract

Metastatic breast cancer (MBC) represents a significant public health problem, because approximately 33% of the 1 million women who are diagnosed annually worldwide with early stage disease eventually will experience relapse, and a smaller number of patients present de novo with this disease.1 After diagnosing MBC, clinicians and patients can use prognostic information to guide the selection of appropriate therapies to improve quality of life and maximize survival. Currently available prognostic tools focus on several clinicopathologic features, such as age and time from diagnosis of primary breast cancer, as well as tumor-related factors, like expression levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Although useful, this approach is limited because of the extensive heterogeneity in breast cancer biology and variable responses to treatments like endocrine therapy, chemotherapy, and novel targeted agents.2 Therefore, a more refined prognostic system is desirable, because this could guide the selection of more effective therapies and allow greater individualization of treatment.

Positron emission tomography/computed tomography (PET/CT) is a widely used diagnostic tool that combines anatomic imaging with functional imaging using [18F]-2-fluoro-2-deoxy-D-glucose (FDG), a biomarker of cellular metabolism. This yields quantitative information about tumor activity by assigning a standardized uptake value (SUV) as a measurement of the relative uptake of FDG in a given lesion. The improved diagnostic performance of PET/CT imaging over conventional imaging (such as ultrasound, bone scan, and CT alone) has been investigated in a variety of settings, including for the staging of high-risk patients with early breast cancer3, 4 and in the detection of bone metastases in patients with MBC.5

Although studies have examined PET/CT imaging as a predictor of treatment response in the primary tumor,6, 7 significantly less is known about how PET/CT imaging can be used as a prognostic tool by quantifying radiotracer accumulation in metastases. Limitations in published series include small numbers, lack of histologic correlates, and the intraindividual variation in SUV by body site, which occurs because of a variety of technical reasons, including motion artifact. Therefore, in the current retrospective, single-institution study, we examined baseline FDG avidity on PET/CT images assessed by the maximum SUV (SUVmax), by body site, as a predictor of overall survival (OS) in patients with MBC.


  1. Top of page
  2. Abstract

After we obtained approval from the Institutional Review Board, institutional databases from January 1, 2001 to December 31, 2008 and patients were included if, by report, they had evidence of ≥1 FDG-avid lesion on a PET/CT image that was obtained within 60 days of their MBC diagnosis (Fig. 1). Lesions at any of the following common MBC sites were eligible for inclusion; bone, liver, lymph node (LN), and lung. According to standard staging criteria, patients with axillary LN metastases were included only if they had additional sites of MBC. The date of MBC diagnosis was defined as the date a patient underwent biopsy of a metastatic site (when available) or the date of first radiologic imaging consistent with metastases as assessed by the treating physician. Because of possible confounding effects on image acquisition, patients who had received chemotherapy within 30 days before PET/CT imaging were excluded (Fig. 1). Patients were permitted to be actively receiving endocrine therapy (for early stage or newly diagnosed MBC). Electronic medical records were reviewed to determine known prognostic variables, including age, histology, grade, tumor phenotype (ER, PR, and HER2 expression), first-line treatment administered, and time from early stage disease to MBC as well as OS, which was calculated from the date of MBC diagnosis to the date of either death or last follow-up.

thumbnail image

Figure 1. This is a Consolidated Standards of Reporting Trials (CONSORT) diagram of the current study. MBC indicates metastatic breast cancer; PET/CT ±60 days, positron emission tomography/computed tomography within 60 days of MBC diagnosis; FDG, [18F]-2-fluoro-2-deoxy-D-glucose; LN, lymph node; SUVmax, maximum standardized uptake value.

Download figure to PowerPoint

According to institutional standards PET/CT images from the middle skull to the upper thighs were obtained 60 minutes after administration of 12 to 15 millicuries FDG on 1 of 4 hybrid PET/CT systems; and, using standard formulae, the SUVmax by site (bone, liver, LN and lung) was calculated. For patients who had multiple metastases by site, the single lesion with the highest SUVmax was used for calculations. In a secondary analysis, all PET/CT scans were reviewed by a single investigator who had 7 years of experience in the interpretation of PET/CT (G.A.U.), blinded to survival data, and the SUVmax was recalculated. This demonstrated a close correlation between the SUVmax by report and by secondary review, as measured by the Spearman rank correlation. Therefore, in an attempt to recreate real-world practice, subsequent analyses were based on the SUVmax by original report. At this point, lesions that were deemed unmeasurable by G.A.U. were excluded from analysis, resulting in the exclusion of 21 patients (Fig. 1). OS was estimated for the entire cohort using the Kaplan-Meier method. Cox models were used to correlate OS with standard prognostic variables, irrespective of anatomic site.

All PET/CT images were analyzed by anatomic site, and patients with a lesion at that site were classified based on tertiles of SUVmax. Tertiles (as opposed to quartiles, quintiles, etc) were chosen to balance the flexibility gained by adding more groups with the need to keep group sizes sufficiently large for subgroup analyses. Some patients who had lesions at multiple sites contributed to several analyses. Relations between SUVmax tertiles and OS were assessed using Cox regression. Hazard ratios (HRs) for the highest versus the lowest tertile are reported in the text, and HRs for the middle versus the lowest tertile also are reported in the figures and tables. When a PET/CT variable was identified as significant (P < .1) on site-specific, univariate analysis, multivariate models were built to adjust for that variable. All statistical analyses were performed using the statistical software packages SAS (version 9.2; SAS Institute Inc., Cary, NC) and R (version 2.11.1; R Foundation for Statistical Computing, Vienna, Austria). P values < .05 were considered significant.


  1. Top of page
  2. Abstract

On initial review, we identified 285 patients who underwent PET/CT imaging within 60 days of their MBC diagnosis; and, after a review by the dedicated nuclear radiologist (G.A.U.), 32 patients were excluded (Fig. 1). Therefore, the final analysis included 253 patients (median age, 57 years; range, 27-90 years) who underwent PET/CT imaging a median of 9 days before MBC diagnosis (range, from 58 days before to 59 days after MBC diagnosis). The median time from diagnosis of early stage disease to MBC diagnosis was 2.2 years (range, 0-24.9 years). Other baseline characteristics are provided in Table 1.

Table 1. Baseline Characteristics of Evaluable Patients (N = 253)
Baseline CharacteristicNo. of Patients%
  • Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; PET/CT, positron emission tomography/computed tomography; PR, progesterone receptor.

  • a

    Triple-negative tumors are defined as tumors without expression of ER, PR, and HER2.

  • b

    Other histologies include papillary, colloid, and mixed ductal and lobular carcinomas.

  • c

    These include abnormal liver blood tests or complete blood counts.

  • d

    Stage IV was defined as metastatic disease diagnosed within 60 days of the primary breast tumor diagnosis.

  • e

    These patients had stage I through III disease, but the details were unknown.

  • f

    Treatment was unknown in 2 patients.

  • g

    Endocrine therapy included aromatase inhibitors, antiestrogen alone, etc; chemotherapy, cytotoxic chemotherapy; targeted therapy, anti-HER2 therapy, angiogenesis inhibitors, etc, possibly in combination with either endocrine therapy or chemotherapy.

Tumor phenotype  
 ER/PR positive AND HER2 negative14256
 HER2 positive5421
 Triple negativea5020
 Unknown (missing HER2 status)73
Indications for PET/CT  
 Other abnormal radiology6927
 Locally advanced breast cancer4919
 Abnormal tumor markers3112
 Other abnormal laboratory testc62
 Indication not determined8835
Stage at initial breast cancer diagnosis  
Treatment for early breast cancerf  
 Neoadjuvant/adjuvant chemotherapy13754
 Adjuvant endocrine therapy10843
 Adjuvant radiation9036
First therapy for MBCg  
 Endocrine therapy11646
 Targeted with or without endocrine therapy4919

Most patients (n = 202; 80%) had a history of early stage breast cancer and subsequently developed metastatic disease. In the remaining 51 patients (20%), MBC was diagnosed within 60 days of primary breast tumor diagnosis. Almost all patients (n = 214; 85%) had invasive ductal carcinoma and ER/PR-positive, HER2-negative was the largest subgroup (n = 142; 56%). Most patients (n = 116; 46%) received endocrine therapy as their first-line treatment. Seventy-four patients (29%) received chemotherapy, and 49 patients (19%) received targeted therapy, possibly combined with chemotherapy or endocrine therapy (Table 1).

Table 2. Maximum Standardized Uptake Value by Disease Site As Prognostic Variables
Disease SiteSUVmax: Median (Range)PHR [95% CI]
  1. Abbreviations: CI, confidence interval; HR, hazard ratio; Ref, reference category; SUVmax, maximum standardized uptake value.

Bone, N = 141 <.001 
 Low tertile4.7 (2.1-5.8) Ref
 Middle tertile7.2 (5.9-9.2) 1.36 [0.76-2.44]
 High tertile11.2 (9.3-29.6) 3.13 [1.79-5.48]
Liver, N = 46 .18 
 Low tertile5.4 (3.6-6.2) Ref
 Middle tertile9.0 (6.3-11.1) 1.86 [0.82-4.19]
 High tertile15.5 (11.2-51.2) 2.07 [0.90-4.76]
Lymph node, N = 149 .31 
 Low tertile4.2 (1.2-5.9) Ref
 Middle tertile7.5 (6.0-9.5) 1.44 [0.89-2.31]
 High tertile13.6 (9.6-34.0) 1.13 [0.69-1.88]
Lung, N = 62 .095 
 Low tertile2.3 (1.1-3.2) Ref
 Middle tertile5.1 (3.3-7.4) 1.08 [0.45-2.62]
 High tertile11.3 (7.5-24.0) 2.20 [0.97-4.95]

Overall, 103 patients (41%) had evidence of visceral metastases (defined as lung or liver disease) on PET/CT images. According to anatomic site, the numbers of patients with metastases on PET/CT images were as follows; bone, 141 patients (56%); liver, 46 patients (18%); LN, 149 patients (59%); and lung, 62 patients (25%). In total, 228 patients (90%) had at least 1 biopsy result that confirmed the MBC diagnosis. Among the patients with FDG-avid lesions, according to anatomic site, the numbers with positive biopsies were as follows: bone, 71 of 141 patients (50%); liver, 30 of 46 patients (65%); LN, 44 of 149 patients (30%); and lung, 37 of 62 patients (60%). At median follow-up of 40 months, 152 patients (60%) had died, and the median OS was 40 months (95% confidence interval, 33-47 months).

Positron Emission Tomography/Computed Tomography Review

A review of all available PET/CT scans demonstrated a close correlation between the SUVmax by original report and by independent review (G.A.U.). The Spearman correlation for these analyses by site was as follows; bone, 0.90; liver, 0.90; LN, 0.88; and lung, 0.85. The definition of tertiles translated into broadly similar SUVmax values in bone, liver, and LN (approximately <6, 6-10, and >10). However, lower cutoffs were defined in the lung tertiles (<3.4, 3.4-7.4, and >7.4) (Table 2).

Standard Prognostic Variables

We first examined known prognostic variables for the whole cohort irrespective of disease site and demonstrated the inferior OS of patients with triple-negative disease (negative for ER, PR, and HER2; HR, 3.0) compared with ER/PR-positive and HER2-negative disease (P < .01). Similarly, patients who had visceral metastases (N = 103) had inferior survival (HR, 1.4; P = .03) compared with patients who did not. Conversely, A longer time from primary breast cancer to MBC diagnosis was associated with improved OS (P < .01; HR, 0.9 and 0.5 for 3-5 years and >5 years, respectively, vs <3 years). Patients who received targeted therapy (including with endocrine therapy or chemotherapy) or chemotherapy alone in the first-line setting had significantly decreased survival (P < .001; HR, 1.6 and 3.5, respectively) compared with patients who received endocrine therapy.

Maximum Standard Uptake Value As a Prognostic Variable

A strong correlation between the SUVmax in bone and OS was observed (P < .001) (Table 3). By using the tertile with the lowest SUVmax as the reference group (median, 4.7; range, 2.1-5.8), patients in the highest tertile of SUVmax (median, 11.2, range, 9.3-29.6) had the shortest survival (HR, 3.13) (Fig. 2A). The magnitude of this effect was greater than that for some of the other prognostic variables that were assessed in the bone cohort, such as the presence of visceral metastases (HR, 2.7; P < .001), but it was smaller than the effect of other variables, such as triple-negative histology (HR, 4.16; P < .001). Receipt of targeted therapy and chemotherapy in the first-line setting were associated with inferior OS (HR, 1.4 and 3.5, respectively; P < .001).

Table 3. Standardized Uptake Value in Bone As a Prognostic Variable: Cox Model for Overall Survival
 Univariate Analysis, N = 141Multivariate Analysis, N = 120
VariableMedian [Range] or No. of Patients/Total No. (%)PHR [95% CI]aPHR [95% CI]a
  • Abbreviations: CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; MBC, metastatic breast cancer; PR, progesterone receptor; Ref, reference category; SUVmax, maximum standardized uptake value.

  • a

    HRs shown are for a 1-unit increase in the covariate (age) or compared with the reference category. Multivariate models were built to adjust for tumor phenotype and variables with P < 0.1 on univariate analysis.

  • b

    All patients had grade 2 or 3 disease; the comparison here is for grade 3 versus grade 2.

  • c

    Endocrine therapy included aromatase inhibitor, antiestrogen alone, etc; chemotherapy, cytotoxic chemotherapy; targeted therapy, anti-HER2 therapy, angiogenesis inhibitor, etc, in combination with either endocrine therapy or chemotherapy.

SUVmax <.001 .002 
 Low tertile4.7 [2.1-5.8]RefRef
 Middle tertile7.2 [5.9-9.2]1.36 [0.76-2.44]2.17 [1.13-4.17]
 High tertile11.2 [9.3-29.6]3.13 [1.79-5.48]3.19 [1.64-6.20]
Tumor phenotype <.001 .021 
 ER/PR positive AND HER2 negative92/138 (67)RefRef
 HER2 positive26/138 (19)1.20 [0.68-2.13]0.64 [0.28-1.47]
 Triple negative20/138 (15)4.16 [2.32-7.48]2.82 [1.18-6.74]
Grade 3b89/122 (73).0921.62 [0.92-2.85].0371.92 [1.04-3.56]
Visceral metastases40 (28)<.0012.70 [1.73-4.23].0072.38 [1.26-4.50]
Age, y57.0 [27.0-89.0].450.99 [0.97-1.01]  
Histology .135   
 Ductal117/140 (84)Ref  
 Lobular12/140 (9)1.05 [0.58-1.91]  
 Other11/140 (8)0.60 [0.36-1.02]  
Time from primary breast cancer to MBC diagnosis: Categorical, y .135   
 <376 (54)Ref  
 3-521 (15)1.05 [0.58-1.91]  
 >544 (31)0.60 [0.36-1.02]  
First therapy for MBCc <.001 0.225 
 Endocrine therapy77 (56) Ref Ref
 Targeted with or without chemotherapy/endocrine therapy27 (20) 1.44 [0.77-2.67] 1.02 [0.42-2.43]
 Chemotherapy33 (24) 3.53 [2.13-5.86] 1.95 [0.84-4.51]
thumbnail image

Figure 2. Overall survival and the maximum standardized uptake value (SUV) are illustrated according to disease by site. Kaplan-Meier overall survival curves were calculated from the date of metastatic breast cancer diagnosis by tertile of the maximum SUV subdivided into (Top Left) bone, (Top Right) liver, (Bottom Left) lymph node, and (Bottom Right) lung as determined from the original positron emission tomography/computed tomography images.

Download figure to PowerPoint

It is noteworthy that grade (P = .09), age (P = .45), histologic subtype (P = .95), and time from primary breast cancer to MBC diagnosis (P = .14) had no significant effect on prognosis (Table 3). We also examined the impact of endocrine therapy at the time of PET/CT imaging and observed no effect on prognosis (P = .62; N = 50 patients on PET images; results not shown).

A greater risk of death was also observed among patients with higher SUVmax in other metastatic sites (liver, LN, and lung), but this achieved statistical significance only in bone (Table 2, Fig. 2B-D). Multivariate models were constructed by site, as described above. In multivariate analyses, the prognostic effect of SUVmax in bone was maintained (P = .002) after correcting for known prognostic variables (Table 3).


  1. Top of page
  2. Abstract

To the best of our knowledge, this retrospective study represents the first large series to correlate FDG avidity on PET/CT images and OS in patients with newly diagnosed MBC, and it has several key findings. First, the SUVmax in bone was strongly correlated with OS, and this effect was maintained in multivariate analyses after correction for tumor phenotype, grade, and the presence of visceral metastases—the prognostic variables that had P values < .1 on univariate analysis. Second, a greater risk of death was also observed among patients who had a higher SUVmax in other metastatic sites (liver, LN, and lung), but the difference did not reach statistical significance. Third, an independent review of PET/CT images demonstrated that the SUVmax was highly reproducible by the reader and could be applied outside of a specialist center. Taken together, these findings suggest a possible role for PET/CT imaging as an additional prognostic tool for patients with newly diagnosed MBC.

Because cancers typically demonstrate greater than physiologic metabolic activity with high glucose uptake, higher FDG uptake on a PET/CT image may be indicative of a more aggressive phenotype. In a variety of malignancies, a higher SUVmax at diagnosis has been associated with inferior survival.8-18 In breast cancer, there are significant challenges to the use of PET/CT imaging as a prognostic tool, including extensive tumor heterogeneity, variable uptake of FDG, and differential response to subsequent treatment. Higher SUV correlates with a variety of adverse prognostic variables, including tumor grade, HER2 expression, ER negativity, and greater numbers of circulating tumor cells.17, 19-22 The use of PET/CT imaging in a prognostic model is compounded further by differential site-specific metastases for biologic subgroups of breast cancer. For example, strong expression of ER and PR, like what occurs in lobular carcinoma, is associated with a relative increased risk of bone metastases and lower SUV values on PET/CT images.22 Therefore, in an attempt to take into account variable tumor biology as well as intraindividual variation in FDG uptake, we examined SUVmax at individual anatomic sites and corrected for known prognostic variables that were identified as significant on univariate analysis.

In our study, patients who had bone metastases (N = 141) and the highest SUVmax tertile (9.3-29.6) had inferior survival compared with patients in the lowest tertile (2.1-5.8; HR, 3.13; P < .001). This effect was maintained in multivariate analyses (HR, 3.19; P = .002) after correcting for known prognostic variables. Similar findings were observed in patients who had metastases in liver (N = 46; HR, 2.07), LN (N = 149; HR,1.1), and lung (N = 62; HR, 2.2), although these results did not reach statistical significance (P = .18, P = .31, and P = .095, respectively).

The current study has several strengths. First, this was a large series that included a broad representation of various subgroups of breast cancer, including 54 patients (21%) with HER2-positive disease and 50 patients (20%) with triple-negative breast cancer. Second, 90% of patients had at least 1 biopsy confirming the diagnosis of MBC (the gold standard), which contrasts to some other series in which the diagnostic performance of PET/CT imaging was compared with other imaging modalities and the results were confounded by the variable performance of the comparator. Third, we correlated FDG uptake (SUVmax) with OS, which is a clean endpoint, as this considers both variable tumor biology and treatment administered. Because the median OS of patients with MBC is 2 to 3 years,2 our results are relatively mature (median follow-up, 40 months). Finally, SUVmax values, which were rereviewed by a single investigator, were highly correlated with the values abstracted from the electronic medical record. We opted to use SUVmax by report in this study, because this reflects real-world practice, in which clinical decisions are made based on PET/CT reports, and selected cases are reviewed on an individual basis.

There are limitations to the current study, which was retrospective, did not assess tumor:background ratios, and included a heterogeneous population both in terms of variable follow-up imaging (timing and modality) and treatment regimens administered. Because not all patients at our institution with possible MBC underwent PET/CT imaging or had FDG-avid disease, selection bias may have played a role. Although 90% of patients underwent a biopsy of at least 1 site, we cannot be absolutely sure that all of the FDG-avid lesions observed on PET/CT images truly represented MBC. For example, although 44 patients in the LN analysis had biopsy-proven MBC in LN, this does not preclude the possibility that many false-positive, high SUVmax values (eg, reactive LNs) were included incorrectly in the correlation between SUVmax and OS. Furthermore, we examined PET/CT imaging from only 1 time-point and, thus, are unable to comment on the predictive effect of PET/CT imaging (with regard to treatment effect). Finally, because this was a retrospective study, the cost-effectiveness of PET/CT imaging could not be assessed.

Several studies have investigated the possible correlation between changes in SUVmax and response (or lack thereof).6, 7, 23-26 In both the preoperative and metastatic settings, a decline in the SUVmax has been associated with tumor response to endocrine therapy and chemotherapy and may be useful to identify a group of patients who are resistant to therapy.6, 7, 23, 27 Furthermore, it has been suggested that PET/CT imaging may be a superior predictor of progression-free survival in patients with bone metastases compared with other novel approaches, such as enumerating circulating tumor cells.26 In fact, emerging data indicate that PET/CT imaging is superior to conventional imaging, such as radionuclide bone scans, for detecting bone metastases from breast cancer.5, 28-30 However, caution is advised, because most data are from retrospective studies, variations in FDG response have been reported by body site, and the choice of therapy and sequence themselves may have an impact on changes in the SUVmax.27, 31

Significant challenges remain in defining the optimum use of PET/CT imaging in MBC. Some investigators have attempted to define specific cutoffs for SUV to define subgroups that may have inferior survival or may benefit most from selected therapies.19 However, given the variation in SUV and differential impact on survival by site, this may not be reproducible; and, if cutoffs are appropriate, then site-specific cutoffs may be advised. In this regard, the SUVmax may be a suboptimal PET/CT parameter in isolation, because it does not factor the size or the number of metastatic lesions into the analysis. Alternative PET/CT prognostic variables may include mean SUV, metabolically active volume, functional lesion volume, or total lesion glycolysis, all of which can be calculated using modern software.32 The composite measurement, total lesion glycolysis, is an attractive PET/CT parameter, because it attempts to overcome some of these limitations by incorporating metabolic volume into the assessment of FDG avidity.33 Therefore, currently, we are investigating total lesion glycolysis as a prognostic variable in patients with newly diagnosed MBC. An alternative approach is the use of novel radiotracers for subgroups of breast cancer, such as patients with HER2-positive disease, designed to offer greater specificity; however, to date, no dominant tracer has demonstrated superiority to FDG.34-37 Ultimately, prospective studies will be needed to individualize parameters and tracers for PET/CT imaging. Nonetheless, we hope that PET/CT imaging has a future role in novel drug development, in individualizing therapeutic approaches by selecting appropriate initial therapies for patients, and as an early signal to change therapy in patients who are not benefiting from a treatment.

In conclusion, in this large, retrospective study of patients who had chemotherapy-naive, newly diagnosed MBC, an increased SUVmax in bone was correlated with inferior survival. Similar effects were noted at other metastatic sites but did not reach statistical significance. These findings suggest that PET/CT imaging is a potential prognostic tool for patients who have newly diagnosed MBC.


  1. Top of page
  2. Abstract

No specific funding was disclosed.


The authors made no disclosures.


  1. Top of page
  2. Abstract
  • 1
    Stewart BW, Kleihues P, eds. World Cancer Report. Lyon, France: IARC Press; 2003.
  • 2
    Morris PG, McArthur HL, Hudis CA. Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother. 2009; 10: 967-981.
  • 3
    Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008; 26: 4746-4751.
  • 4
    Groheux D, Moretti JL, Baillet G, et al. Effect of F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008; 71: 695-704.
  • 5
    Morris PG, Lynch C, Feeney JN, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 2010; 28: 3154-3159.
  • 6
    Ueda S, Tsuda H, Saeki T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2011; 18: 299-308.
  • 7
    Martoni AA, Zamagni C, Quercia S, et al. Early F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer. 2010; 116: 805-813.
  • 8
    Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009; 21: 1008-1015.
  • 9
    Zhang B, Li X, Lu X. Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma. Acta Otolaryngol. 2010; 130: 756-762.
  • 10
    Kim YS, Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK. Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (stage I and II) non-small cell lung cancer. Neoplasma. 2011; 58: 245-250.
  • 11
    Chihara D, Oki Y, Onoda H, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011; 93: 502-508.
  • 12
    van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007; 43: 1392-1398.
  • 13
    Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010; 5: 612-619.
  • 14
    Rizk N, Downey RJ, Akhurst T, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg. 2006; 81: 1076-1081.
  • 15
    Nakamura K, Hongo A, Kodama J, Hiramatsu Y. The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer. Gynecol Oncol. 2011; 123: 82-87.
  • 16
    Suzuki A, Xiao L, Hayashi Y, et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011; 117: 4823-4833.
  • 17
    De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009; 27: 3303-3311.
  • 18
    Downey RJ, Akhurst T, Gonen M, Park B, Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007; 133: 1419-1427.
  • 19
    Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008; 38: 250-258.
  • 20
    Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011; 38: 426-435.
  • 21
    Tchou J, Sonnad SS, Bergey MR, et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol. 2010; 12: 657-662.
  • 22
    Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008; 112: 995-1000.
  • 23
    Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011; 22: 307-314.
  • 24
    Couturier O, Jerusalem G, N'Guyen JM, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006; 12: 6437-6443.
  • 25
    Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008; 247: 189-196.
  • 26
    De Giorgi U, Mego M, Rohren EM, et al. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010; 51: 1213-1218.
  • 27
    Schneider-Kolsky ME, Hart S, Fox J, et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET [serial online]. Breast Cancer Res. 2010; 12: R37.
  • 28
    Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005; 19: 573-579.
  • 29
    Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003; 38: 250-256.
  • 30
    Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998; 16: 3375-3379.
  • 31
    Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010; 22: 818-827.
  • 32
    Torigian DA, Lopez RF, Alapati S, et al. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT. Hell J Nucl Med. 2011; 14: 8-14.
  • 33
    Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The Visual Response Score and the change in total lesion glycolysis. Clin Positron Imaging. 1999; 2: 159-171.
  • 34
    Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A. Oncologic PET tracers beyond [F]FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging. 2008; 52: 50-65.
  • 35
    Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004; 22: 701-706.
  • 36
    Akhurst T, Morris PG, Modi S, et al. Positron emission tomography (PET) with radiolabeled F(ab′)2-trastuzumab fragments in patients (pts) with HER2-positive metastatic breast cancer (MBC): initial feasibility results: Paper presented at: 2008 ASCO Breast Cancer Symposium; Washington, DC; September 5-7, 2008. Abstract 79.
  • 37
    Morris PG, Akhurst T, Smith-Jones P, et al. Cu-64-trastuzumab imaging in patients (pts) with HER2-positive metastatic breast cancer (MBC) receiving trastuzumab (T) therapy: initial results. Paper presented at: 2009 ASCO Breast Cancer Symposium; San Francisco, CA; October 8-10, 2009. Abstract 83.